KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Johnson & Johnson (JNJ) EBT (2016 - 2026)

Johnson & Johnson's EBT history spans 18 years, with the latest figure at $6.0 billion for Q1 2026.

  • On a quarterly basis, EBT fell 56.06% to $6.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $24.9 billion, a 6.25% decrease, with the full-year FY2025 number at $32.6 billion, up 95.25% from a year prior.
  • EBT hit $6.0 billion in Q1 2026 for Johnson & Johnson, up from $5.0 billion in the prior quarter.
  • Over the last five years, EBT for JNJ hit a ceiling of $13.6 billion in Q1 2025 and a floor of -$1.3 billion in Q2 2023.
  • Historically, EBT has averaged $5.3 billion across 5 years, with a median of $5.2 billion in 2022.
  • Biggest five-year swings in EBT: tumbled 124.74% in 2023 and later soared 388.58% in 2024.
  • Tracing JNJ's EBT over 5 years: stood at $5.2 billion in 2022, then decreased by 6.69% to $4.8 billion in 2023, then decreased by 19.46% to $3.9 billion in 2024, then increased by 27.76% to $5.0 billion in 2025, then rose by 20.62% to $6.0 billion in 2026.
  • Business Quant data shows EBT for JNJ at $6.0 billion in Q1 2026, $5.0 billion in Q4 2025, and $7.5 billion in Q3 2025.